Celcuity (CELC) Return on Capital Employed (2017 - 2025)
Celcuity (CELC) reported Return on Capital Employed of 8.7% for Q4 2025, up 162.0% on a YoY basis from 3.32% in Q4 2024, and up 63.62% quarter-over-quarter from 23.93% in Q3 2025.
Celcuity (CELC) Return on Capital Employed (2017 - 2025) Analysis & Trends
Celcuity has reported Return on Capital Employed for 9 years, with the latest figure at 8.7% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed rose 162.0% year-over-year to 8.7%; the trailing twelve-month figure through Dec 2025 stood at 8.7% (up 162.0% YoY), and the FY2025 full-year result was 11.93%, up 66.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 8.7%, up from 23.93% in the prior quarter.
- The five-year high for Return on Capital Employed was 7.2% in Q4 2021, with the low at 56.41% in Q2 2021.
- Historically, Return on Capital Employed has averaged 29.26% across 5 years, with a median of 33.73% in 2022.
- The largest YoY upside for Return on Capital Employed was 6775 bps in 2021 against a maximum downside of 4294 bps in 2021.
- Celcuity's Return on Capital Employed stood at 7.2% in 2021, then sank by 382 bps to 34.67% in 2022, then dropped by 25 bps to 43.4% in 2023, then jumped by 76 bps to 10.32% in 2024, then advanced by 16 bps to 8.7% in 2025.
- The last three Return on Capital Employed figures came in at 8.7% (Q4 2025), 23.93% (Q3 2025), and 35.32% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -107.40% |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -50.43% |
| 10 | Celcuity | 4.14 Bn | 3.42 Bn | - | -8.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -8.70% |
| Sep 30, 2025 | -23.93% |
| Jun 30, 2025 | -35.32% |
| Mar 31, 2025 | -18.68% |
| Dec 31, 2024 | -10.32% |
| Sep 30, 2024 | -37.65% |
| Jun 30, 2024 | -38.67% |
| Mar 31, 2024 | -44.03% |
| Dec 31, 2023 | -43.40% |
| Sep 30, 2023 | -42.99% |
| Jun 30, 2023 | -32.79% |
| Mar 31, 2023 | -27.01% |
| Dec 31, 2022 | -34.67% |
| Sep 30, 2022 | -19.19% |
| Jun 30, 2022 | -9.57% |
| Mar 31, 2022 | -13.77% |
| Dec 31, 2021 | -7.20% |
| Sep 30, 2021 | -38.12% |
| Jun 30, 2021 | -56.41% |
| Mar 31, 2021 | -42.73% |